β-Blocker-Therapie bei akutem Myokardinfarkt

  • S. H. Hohnloser
  • T. Klingenheben
  • G. Grönefeld


Wenige therapeutische Strategien in der Kardiologie sind ähnlich gut untersucht worden wie die Frage der antiadrenergen Therapie bei Patienten mit akutem Myokardinfarkt. In den vergangenen 10–15 Jahren sind insgesamt 49 prospektive kontrollierte randomisierte Studien durchgeführt worden, die die Wirksamkeit einer Therapie mit β-Blockern in der frühen Infarktphase untersucht haben. Im vorliegenden Beitrag wird versucht, die Ergebnisse dieser Studien kritisch zu werten und der Frage nachzugehen, inwieweit die Schlußfolgerungen aus diesen Untersuchungen Eingang in den klinischen Alltag gefunden haben.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    ACC/AHA Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (1990) ACC/AHA guidelines for the early management of patients with acute myocardial infarction. Circulation 82: 664–707.CrossRefGoogle Scholar
  2. 2.
    Antman EM, Berlin JA (1992) Declining incidence of ventricular fibrillation in myocardial infarction. Implications for the prophylactic use of lidocaine. Circulation 86: 764–773.Google Scholar
  3. 3.
    Chiriboga D, Yarzebski J, Goldberg RL, Gore JM, Alpert JS (1994) Temporal trends (1975 through 1990) in the incidence and case-fafality rates of primary ventricular fibrillation complicating acute myocardial fibrillation: A communitywide perspective. Circulation 89: 998–1003.PubMedGoogle Scholar
  4. 4.
    Corbalan R, Verrier RL, Lown B (1976) Differing mechanisms for ventricular vulnerability during coronary artery occlusion and release. Am Heart J 92: 223–230.PubMedCrossRefGoogle Scholar
  5. 5.
    Fitzgerald JD, Singh BN (1994) Effects of β-Blockers on cardiovascular morbidity and mortality in coronary artery disease. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL (eds) Cardiovascular pharmacology and therapeutics. Churchill Livingstone, New York, pp 511–524.Google Scholar
  6. 6.
    Frishman WH, Lazar EJ (1990) Reduction in mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: A new hypothesis regarding the cardioprotective action of β-adrenergic blockade. Am J Cardiol 66: 66G–70G.PubMedCrossRefGoogle Scholar
  7. 7.
    Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1: 397–402.Google Scholar
  8. 8.
    Han J, De Jalon G, Moe GK (1994) Adrenergic effects on ventricular vulnerability. Circ Res 14: 516ff.Google Scholar
  9. 9.
    Heidbüchel H, Tack J, Vanneste L, Ballet A, Ector H, Werf F van de (1994) Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence. Circulation 89: 1051–1059.PubMedGoogle Scholar
  10. 10.
    Hjalmarson A (1988) International beta-blocker review in acute and postmyocardial infarction. Am J Cardiol 61: 26B–29B.PubMedCrossRefGoogle Scholar
  11. 11.
    Hohnloser SH, Zabel M, Kasper W, Meinertz T, Just H (1991) Assessment of/coronary artery patency after thrombolytic therapy: Accurate prediction utilizing the combined analysis of three noninvasive markers. J Am Coll Cardiol 18: 44–49.PubMedCrossRefGoogle Scholar
  12. 12.
    Hohnloser SH, Meinertz T, Klingenheben T, Sydow B, Just H (1991) Usefulness of esmolol in unstable angina pectoris. Am J Cardiol 67: 1319–1323.PubMedCrossRefGoogle Scholar
  13. 13.
    Hohnloser SH, Zabel M, Olschewski M, Just H (1992) Arrhythmias during the acute phase of reperfusion therapy for acute myocardial infarction: Effects of beta-adrenergic blockade. Am Heart J 123: 1530–1535.PubMedCrossRefGoogle Scholar
  14. 14.
    International Collaborative Study Group (1984) Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 310: 9–15.CrossRefGoogle Scholar
  15. 15.
    ISIS-1 Collaborative Group (1986) Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet: 2 (3498): 57–66.Google Scholar
  16. 16.
    ISIS-1 Collaborative Group (1988) Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. Lancet 1: 921–923.Google Scholar
  17. 17.
    ISIS-2 Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction: ISIS-2. Lancet 2: 349–360.Google Scholar
  18. 18.
    Jennings RB, Reimer KA (1974) Salvage of ischemic myocardium. Mod Concepts Cardiovasc Dis 1974;43: 125–137.Google Scholar
  19. 19.
    Jewitt DE, Mercer CJ, Reid J, Valori C, Thomas M, Shillingford JP (1969) Free noradrenaline and adrenaline excretion in relation to the development of cardiac arrhythmias and heart failure in patients with acute myocardial infarction. Lancet 1: 635–641.PubMedCrossRefGoogle Scholar
  20. 20.
    Klingenheben T, Hohnloser SH, Just H (1992) Kurzwirksame Beta-Rezeptorenblocker - eine neue Substanzklasse in der Intensivmedizin. Intensivmed 29: 435–441.Google Scholar
  21. 21.
    Malliani A, Schwartz PJ, Zanchetti A (1969) A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol 217: 703–709.PubMedGoogle Scholar
  22. 22.
    MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Europ Heart J 6: 199–226.Google Scholar
  23. 23.
    Miura N, Thomas R, Ganz W et al. (1979) The effect of delay in propranolol adiminstration on reduction of myocardial infarct size after experimental coronary artery occlusion in dogs. Circulation 59: 1148–1157.PubMedGoogle Scholar
  24. 24.
    Nadeau RA, Champlain J de (1979) Plasma catecholamines in acute myocardial infarction. Am Heart J 98: 548–554.PubMedCrossRefGoogle Scholar
  25. 25.
    Norris RM, Barnaby PF, Brown MA, Geary GG, Clarke ED, Logan RL, Sharpe DN (1984) Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet: 883–886.Google Scholar
  26. 26.
    Patterson E, Lucchesi BR (1988) Electrophysiologic and antiarrhythmic actions of nadolol: Acute ischemia in the presence of previous myocardial infarction. Am Heart J 116: 1223–1232.PubMedCrossRefGoogle Scholar
  27. 27.
    Patterson E, Lynch JL, Lucchesi BR (1984) Antiarrhythmic and antifibrillatory actions of beta adrenergic receptor antagonist, dl-sotalol. J Pharmacol Exp Ther 230: 519–526.PubMedGoogle Scholar
  28. 28.
    Rapaport E (1991) Should beta-blockers be given immediately and concomitantly with thrombolytic therapy in acute myocardial infarction? Circulation 83: 695–697.PubMedGoogle Scholar
  29. 29.
    Roberts R, Croft C, Gold HK et al. (1984) Effect of propranolol on myocardial infarct size in a randomised, blinded, multicenter trial. N Engl J Med 311: 218–225.PubMedCrossRefGoogle Scholar
  30. 30.
    Roberts R, Rogers WJ, Mueller HS et al. (1991) Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Circulation 83: 422–437.PubMedGoogle Scholar
  31. 31.
    Rossi PRF, Yusuf S, Ramsdale D, Furze L, Sleight P (1983) Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. B M J 286: 506–510.CrossRefGoogle Scholar
  32. 32.
    Ryden L, Ariniego R, Arman K et al. (1983) A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 308: 614–618.Google Scholar
  33. 33.
    Schwartz PJ, Priori SG (1990) Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J. (eds) Cardiac electrophysiology. W.B. Saunders, Philadelphia/PA, pp 330–343.Google Scholar
  34. 34.
    Singh BN (1992) Routine prophylactic lidocaine administration in acute myocardial infarc¬tion: An idea whose time is all but gone ? Circulation 86: 1033–1035.PubMedGoogle Scholar
  35. 35.
    Snow PJD (1965) Effect of propranolol in myocardial infarction. Lancet 2: 551–553.PubMedCrossRefGoogle Scholar
  36. 36.
    Videbaeck J, Christensen NJ, Sterndorff B (1972) Serial determinations of plasma catecholamines in myocardial infarction. Circulation 46: 846–855.Google Scholar
  37. 37.
    Volpi A, Maggioni A, Franzosi MG, Pampallone S, Mauri F, Tognoni G (1987) In-hospital pro-gnosis of patients with acute myocardial infarction complicated by primary ventricular fibrillation. N Engl J Med 317: 257–261.PubMedCrossRefGoogle Scholar
  38. 38.
    Yusuf S, Sleight P, Rossi P et al. (1983) Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 67 (suppl): 32–41.Google Scholar
  39. 39.
    Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: An overview of the randomized trials. Progr Cardiovasc Dis 27: 335–371.CrossRefGoogle Scholar
  40. 40.
    Yusuf SB, Sleight P, Held P, MacMahon S (1990) Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. Circulation 82 (suppl II): III 17–11134.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • S. H. Hohnloser
  • T. Klingenheben
  • G. Grönefeld

There are no affiliations available

Personalised recommendations